ArticleCancer research2025
Intracellular IL1α in Peritumoral Monocytes Induces IL8 Production and Inhibits Mitophagy to Promote Stemness and Metastasis of Hepatocellular Carcinoma.
Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mitophagy interacts with mitochondrial dynamics and biogenesis, acting as a double-edged sword in digestive cancer.iScience · 2026Review
- Hepatocellular carcinoma metastasis-immune microenvironment crosstalk: emerging mechanisms and immunotherapy.Cellular & molecular biology letters · 2026Review
- Advances in mitophagy research in hepatocellular carcinoma: mechanisms and therapeutic implications.Journal of gastrointestinal oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
IL1α is a potent inflammatory cytokine that is released by cell necrosis and activates IL1R. More recently, IL1α has been shown to have intracellular functions. In the current study, we investigated the expression and distinctive role of IL1α in tumor progression. In patients with hepatocellular carcinoma (HCC), IL1α levels were significantly upregulated in monocytes in peritumoral regions compared with nontumoral and intratumoral areas. A glycolytic switch mediated the upregulation of IL1α via NF-κB signaling. The upregulated IL1α was neither secreted by nor displayed on the cell surface of monocytes; instead, IL1α translocated into the nucleus to induce the production of IL8, which effectively enhanced cancer cell stemness and tumor metastasis. Additionally, IL1α bound to mitochondria to inhibit mitophagy, inducing CA12 expression and macrophage accumulation via the mitochondrial reactive oxygen species-hypoxia-inducible factor-1α pathway. In accordance, IL1α expression in peritumoral monocytes was negatively correlated with survival and positively associated with tumor metastasis in patients with HCC. Targeting IL1α+ monocytes or IL8 effectively inhibited tumor progression and enhanced responsiveness to immune checkpoint blockade therapy in mouse HCC models. Overall, these results revealed an intracellular regulatory role of IL1α in modifying the protumor functions of monocytes within specific tumor microenvironments and pointed to both IL1α and its downstream IL8 as potential diagnostic and therapeutic targets for HCC. SIGNIFICANCE: Glycolysis upregulates intracellular IL1α that reprograms peritumoral monocytes by translocating into the nucleus to induce prometastatic IL8 production or binding to mitochondria to stimulate prosurvival CA12 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.